ArticleMedicine2018
Effect of linezolid on serum PCT, ESR, and CRP in patients with pulmonary tuberculosis and pneumonia.
Article in Medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 24 citations in OpenAlex.
- Adverse effects of linezolid in the treatment of drug-resistant tuberculosis: a scoping review.Breathe (Sheffield, England) · 2026Review
- Development of a Rifapentine-Loaded Alendronate-Conjugated PLGA-PEG Nanosystem: A Novel Bone-Targeted Strategy for Osteoarticular Tuberculosis Treatment with Enhanced Drug Delivery and Bone Regeneration.International journal of nanomedicine · 2025Article
- Value of inflammatory mediator profiles and procalcitonin in predicting postoperative infection in patients with hypertensive cerebral hemorrhage.World journal of clinical cases · 2022Article
- B and T lymphocyte attenuator as a C-reactive protein and IgA associated auxiliary diagnostic marker for pulmonary tuberculosis: a case-control study.Annals of translational medicine · 2022Article
- Article
- Research on the Correlation of Peripheral Blood Inflammatory Markers with PCT, CRP, and PCIS in Infants with Community-Acquired Pneumonia.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- A scoring system developed from a nomogram to differentiate active pulmonary tuberculosis from inactive pulmonary tuberculosis.Frontiers in cellular and infection microbiology · 2022Article
- Combined analysis of whole blood interferon gamma release assay and complete blood count analysis for rapid discrimination of active tuberculosis and latent tuberculosis infection.Journal of clinical tuberculosis and other mycobacterial diseases · 2021Article
- Mean platelet volume (MPV): new diagnostic indices for co-morbidity of tuberculosis and diabetes mellitus.BMC infectious diseases · 2021Article
- Awareness and Mental Health of Male Drug Addicts With Tuberculosis During the COVID-19 Pandemic.Frontiers in psychiatry · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe continuous development of drug-resistant tuberculosis in recent years has brought new attention to tuberculosis. linezolid is usually used to treat infection in patients with pulmonary tuberculosis and pneumonia, for it has good effects on Mycobacterium tuberculosis, and has strong antibacterial activity on the drug-resistant strain. This study aims to investigate the effects of linezolid on serum procalcitonin (PCT), erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) in patients with pulmonary tuberculosis and pneumonia.
methodsForty patients with pulmonary tuberculosis and pneumonia were divided into 2 groups: observation group (n = 20), patients treated with linezolid; control group (n = 20), patients treated with moxifloxacin. At 14 days, one month and 3 months of treatment, changes in serum PCT, ESR, CRP, and bacterial eradication rate (negative conversion rate) were compared between the 2 groups, and the incidence of adverse reactions was compared.
resultsSerum PCT, ESR, and CRP in the 2 groups were significantly lower after 14 days of treatment than before treatment (P < .05), the decrease was more significant in the observation group, and the differences in ESR and CRP were statistically significant (t = 2.199, 2.494, P < .05). Furthermore, the negative conversion rate was higher in the observation group, but the difference was not statistically significant (P > .05). At one month of treatment, serum PCT, ESR, and CRP were lower in the observation group, and the difference in CRP was statistically significant (t = 3.274, P < .05). Furthermore, the negative conversion rate was slightly higher in the observation group, but the difference was not statistically significant (P > .05). At 3 months of treatment, differences in PCT, ESR, and CRP were not statistically significant, and the negative conversion rate was the same between the 2 groups. Furthermore, the incidence of adverse reactions was higher in the observation group, but all were mild, and the differences between these 2 groups were not statistically significant (P > .05).
conclusionIn the treatment of tuberculosis and pneumonia, linezolid can improve serum PCT, ESR, and CRP levels, and eradicate bacteria. However, adverse reactions should be strictly monitored to ensure its safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.